Last 12 months
Inside the activity.
2 purchase rows · 5 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 2 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2017 Filed May 3, 2017 17:00 UTC |
HAYDEN DONALD J JRDirector
|
Exercise / conversionCommon Stock | 20,000 | $0.85 | $17,000.00 |
DisclosureSEC source: 0000899243-17-011652 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,599 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 24, 2017 Filed Apr 27, 2017 01:02 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 1,395 | $21.40 | $29,853.00 |
DisclosureSEC source: 0000899243-17-010933 · doc4.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.40 to $21.425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 27, 2017 01:02 UTC |
Mills Kenneth T.Director · President and CEO
|
SaleCommon Stock | 14,045 | $20.94 | $294,102.30 |
DisclosureSEC source: 0000899243-17-010933 · doc4.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,395 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.40 to $21.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 21:00 UTC |
Vasista VittalChief Financial Officer
|
SaleCommon Stock | 327 | $21.42 | $7,004.34 |
DisclosureSEC source: 0000899243-17-010931 · doc4.xml · nonDerivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,712 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $21.40 to $21.45. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 21:00 UTC |
Vasista VittalChief Financial Officer
|
SaleCommon Stock | 2,773 | $20.95 | $58,094.35 |
DisclosureSEC source: 0000899243-17-010931 · doc4.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,039 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.40 to $21.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 24, 2017 Filed Apr 26, 2017 21:00 UTC |
HAYDEN DONALD J JRDirector
|
SaleCommon Stock | 10,000 | $20.98 | $209,800.00 |
DisclosureSEC source: 0000899243-17-010932 · doc4.xml · nonDerivative · entry 1 HAYDEN DONALD J JR · CIK 0001202285 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,599 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $20.45 to $21.425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 27, 2017 Filed Mar 29, 2017 17:15 UTC |
Danos OlivierChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $20.35 | $0.00 |
DisclosureSEC source: 0000899243-17-008828 · doc4.xml · derivative · entry 1 Danos Olivier · CIK 0001701180 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-03-26 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 3/27/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:01 UTC |
Ali FarazChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,200 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000698 · doc4.xml · derivative · entry 1 Ali Faraz · CIK 0001667937 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,200 Underlying: Common Stock · 25,200 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:01 UTC |
Mills Kenneth T.Director · President and CEO
|
GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000697 · doc4.xml · derivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:00 UTC |
Vasista VittalChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000693 · doc4.xml · derivative · entry 2 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2017-01-03 F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:00 UTC |
Yoo StephenChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000696 · doc4.xml · derivative · entry 1 Yoo Stephen · CIK 0001652825 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:00 UTC |
Simpson CurranSVP, Technical Operations
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000694 · doc4.xml · derivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 22:03 UTC |
Christmas Patrick J.SVP, General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 11,100 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0000899243-17-000699 · doc4.xml · derivative · entry 1 Christmas Patrick J. · CIK 0001521123 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,100 Underlying: Common Stock · 11,100 shares Expires 2027-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 1/4/2018 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 31, 2016 Filed Jan 6, 2017 17:00 UTC |
Vasista VittalChief Financial Officer
|
GrantCommon Stock | 1,372 | $6.79 | $9,317.94 |
DisclosureSEC source: 0000899243-17-000693 · doc4.xml · nonDerivative · entry 1 Vasista Vittal · CIK 0001652827 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,812 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of July 1, 2016 through December 31, 2016. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2016. Read SEC document |
| December 08, 2016 Filed Dec 12, 2016 22:00 UTC |
Simpson CurranSVP, Technical Operations
|
GrantCommon Stock | 39,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-035308 · doc4.xml · nonDerivative · entry 1 Simpson Curran · CIK 0001346164 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,500 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on December 8, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.